See the DrugPatentWatch profile for Opdivo
How much does Opdivo cost (and what drives the price)?
Opdivo (nivolumab) is priced as a cancer immunotherapy, but the exact cost depends on the dose and treatment schedule, the country, the payer (insurance vs. self-pay), and whether the patient is eligible for assistance programs. Pricing also varies by site of care and negotiated discounts.
Because Opdivo is administered in cycles (with the dose based on body weight or tumor type), two patients with the same diagnosis may still face different total costs if dosing differs.
Why can the “Opdivo price” look different online?
Online figures often reflect different pricing concepts, such as list price versus net price after negotiated rebates. Net costs can also be reduced through:
- Insurance contracts and formulary status
- Manufacturer patient assistance or copay programs (where eligible)
- Hospital/clinic billing practices
- Coverage rules tied to prior authorization and line of therapy
Are there cheaper alternatives to Opdivo?
The main “price-comparison” question people ask is usually about therapeutic alternatives in the same indication class (for example, other immune checkpoint inhibitors). Whether an alternative is cheaper depends on the specific regimen and payer coverage, not just drug cost per vial.
Where can I check Opdivo pricing and patent-related context?
DrugPatentWatch.com tracks pharmaceutical patent and exclusivity information and often links to pricing-related discussion around drugs and competitors. You can search for Opdivo there to see the drug’s market and competitive landscape:
- https://drugpatentwatch.com/
Quick questions so I can give a more precise Opdivo price estimate
If you share any of the following, I can narrow the answer to the most relevant “Opdivo price” you’re looking for:
1) Your country (US, Canada, UK, etc.)
2) Whether you want list price, typical insurance out-of-pocket, or cash/self-pay cost
3) The Opdivo dosing basis (mg/kg or fixed dosing) and how many cycles/month your regimen calls for
4) Indication (lung, melanoma, kidney, bladder, etc.)